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Chemotherapy is usually the first choice for the treatment of many cancer types.
According to the American Cancer Society, more than 100 drugs are currently used for
chemotherapy, alone or in combination with other drugs or treatments. Many more have
been developed as anticancer drug candidates, but only a few of them are expected to
come into clinical practice. These drugs vary widely in their chemical composition, how
they are taken, their usefulness in treating specific forms of cancer, and their side effects.
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Scientists of all kinds have long been intrigued by the
nature, action and potential of natural toxins that pos-
sess exceptional antibacterial and anticancer activities.
These compounds, named enediynes, are among the most
effective chemotherapeutic agents known. Often com-
pared with intelligent weapons, due to the unique struc-
ture and sophisticated mechanism by which they destroy
double-helical DNA, enediyne antibiotics are nowadays
the most promising leaders in the anticancer therapy.
Apart from their diversity, enediyne compounds share
some structural and functional similarities. One fragment
of a structure is responsible for the recognition and trans-
port, another part acts as molecular trigger while the third,
reactive enediyne unit, undergoes Bergman cycloaroma-
tization and causes DNA breakage. Members of the ene-
diyne family are already in clinical use to treat various
cancers, but more general use is limited by their complex
structure, which makes them formidable targets for syn-
thetic chemists. There are three main approaches in the
design of new enediyne-related compounds: improvement
of enediyne »warheads«, increasing the selectivity and
control of chemical or photo-induced activation. This pa-
per gives an overview of naturally occurring enediynes,
their mode of action and efforts undertaken to design ar-
tificial enediyne-related DNA cleaving agents.
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The majority of anticancer drugs affect cell division or DNA synthesis and function
and can be classified as alkylating agents, antimetabolites, anticancer antibiotics, mitotic
inhibitors and plant alkaloids. Some chemotherapeutics do not directly interact with DNA,
but rather target molecular abnormality in certain types of cancer. In addition, some
drugs are used to modulate cancer cell behavior, without directly attacking, like in the
hormone treatment.
Development of new efficient anticancer drugs requires a detailed knowledge of the
mechanism of drug action at the cellular and molecular levels. Since most anticancer
drugs express their activity through the interaction with DNA, extensive research on
DNA-drug complexes was undertaken. In the last decades, efforts in this field resulted
in useful information about DNA conformations and DNA-drug interactions. There are
several ways of interaction between DNA and a drug and they can be classified as fol-
lows (1):
 formation of non-covalent complexes achieved through intercalation, insertion
between base pairs (daunorubicin [DNC] and doxorubicin [DOX]) or groove-
-binding (distamycin A),
 formation of covalent linkage between the DNA and anticancer drug (cisplatin,
mitomycin C),
 binding to the DNA through some other mechanism and breakage of the DNA
backbone (duocarmycin, bleomycin [BLM]/pepleomycin [PEP], enediyne antibio-
tics).
Development of high-resolutions X-ray diffraction and nuclear magnetic resonance
(NMR) techniques, together with thermodynamic studies and molecular modeling made
a great contribution to disclosing the basic principles in DNA-drug interaction (2-4). The
most striking finding that came out of it is that targets for drug’s action are specific reac-
tive, nucleophilic sites distributed on the surface of the double helix. In the minor gro-
ove, N2 of the guanine base is susceptible to drug action and the place where most of the
alkylating agents act. Also, a number of anthracycline DNA-binding drugs form com-
plexes or adducts involving N2 of guanine in the first stage of action (DNR/DOX, Fig.
1). In addition, N3 atom of guanine and adenine in the minor groove is also favorable
for drug action (dystamicin A and duocarmycin, Fig. 1), as well as N7 of guanine, which
is the reactive site for alkylating agents and metal ions. Structural interactions of plati-
num anticancer compounds with DNA have been extensively studied. Cisplatin forms
intrastrand cross-link with two N7 of guanine (Fig. 1), which is converted into a more
stable interstrand bi-dentated adduct (1). It is assumed that the biological activity of
cisplatin is related to the interactions of certain proteins with the cisplatin-DNA adduct.
These interactions are responsible for the tumor cell death, through not fully elucidated
mechanism(s). Some anticancer drugs do not target DNA bases, but rather cleave the
DNA backbone. Bleomycin (BLM) is clinically used in combination chemotherapy for
the treatment of various types of cancers (5). In-site activation and reaction of DNA and
BLM necessitate two cofactors: Fe(II) and O2. Activated BLM is not stable (t1/2 = 2 min at
0 °C in the presence of DNA), it readily abstracts C(4’) hydrogen atom from the deoxy-
ribose backbone of the DNA (Fig. 1) (6). Finally, enediyne antibiotics belong to the fam-
ily of highly potent anticancer agents that bind to specific DNA sequences and cause
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double-stranded DNA lesions. Their positioning within the minor groove is such that
the active form of a drug can abstract two hydrogen atoms from the sugars of opposite
strands. Fig. 1 schematically represents sites of action of some anticancer drugs.
Peptides are generally considered poor therapeutics due to their high flexibility, low
enzymatic stability and polarity, which disable them to pass biological membranes. At
the same time, peptides and proteins are of the key importance in many chronic and in-
fectious disorders. Also, a number of peptides with anticancer use or potential have been
reported (7). Considerable efforts have been invested in designing compounds with im-
proved bioavailability and capability to mimic peptide functions. Laboratory for carbo-
hydrate, peptide and glycopeptide research at the Ru|er Bo{kovi} Institute has a long
tradition in the design, synthesis, analysis, conformations, dynamics and structure-activ-
ity relationship of biologically relevant peptides, glycopeptides and peptidomimetics
(8–16). In recent years, we have been dedicated to carbohydrate-modified amino acids
and peptides and found them suitable models for the study of biological phenomena (8,
9, 11, 13, 16). During that time, conformational preferences of modified peptides estab-
lished by NMR spectroscopy and molecular modelling (10), as well as fragmentation
pathways evidenced by mass spectrometric analysis (12), have widened our knowledge
and added some new »puzzles« necessary to understand complex biological »images«.
Lately, we have decided to enrich the peptidomimetic family with new enediyne-related
members (15). In this paper, general knowledge of naturally occurring enediynes, their
mechanism of action and enediyne-related structures are presented.
135

































































Fig. 1. Schematic presentation of the A-T and G-C base pairs in the minor groove with
designated sites of anticancer drug action.
ENEDIYNE ANTICANCER ANTIBIOTICS
Structure and mechanism of action
Enediyne antibiotics, a relatively new class of anticancer agents, have been a subject
of great interest and intensive research among chemists and biologists since their discovery
in the mid-1980s. They possess an exceptional biological profile owing to their unique
molecular structure, striking mode of action and high potency (17, 18). The first member
of this class, neocarzinostatin chromophore, was described in 1985 (19). Two years later,
the first members of the calicheamicin (20) and esperamicin (21) family were isolated,
followed by the report on dynemicin characterization in 1989 (22). Fig. 2 shows the struc-
tures of some naturally occurring enediyne antibiotics. As highlighted, the common struc-
tural motif among enediyne antibiotics is an enediyne moiety (Z-hexa-1,5-diyn-3-ene)
found captured within a 9- or 10-membered ring.
Apart from their complexity, the structure of enediyne anticancer antibiotics can be
simplified by comparison with modern weapons (Fig. 3). Part of a structure, responsible
for recognition and transport, delivers the whole, yet inactive »package« to the DNA.
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Fig. 2. Naturally occurring enediyne antibiotics.
After docking into the minor groove, the process can start. On-site activation sets for-
ward a molecular trigger; the cascade of reactions ends with contraction of the enediyne
»warhead.« Highly reactive structure formed in this process is capable of the DNA dou-
ble helix breakage.
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Fig. 3. Schematic presentation of the enediyne antibiotic’s mechanism of action.
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Fig. 4. Mechanism of DNA cleavage by the calicheamicin family of enediyne antibiotics.
Calicheamicins (Fig. 2) were the first enediyne antibiotics whose mechanism of ac-
tion was elucidated in more detail. The extended sugar part consists of unusually linked
monosaccharide units and the substituted benzene ring serves as a delivery service,
which binds the molecule to the minor groove of double-helical DNA. Nucleophilic at-
tack on the allylic trisulfide moiety has the function of triggering device activation (Fig.
4). A thiol formed in the first step initiates a cascade of reactions that cause a significant
change in the structural geometry of a molecule. These changes have a special impact on
the enediyne moiety captured within the 10-membered ring. As a consequence of changed
molecule geometry, a process known as Bergman cycloaromatization takes place (23).
Enediyne moiety forms a highly reactive benzene diradical that strips hydrogen atoms
from the sugar phosphate backbone of DNA strands, causing scission of the DNA dou-
ble helix (24).
Bergman cycloaromatization – an insight into the mechanism of activation
In 1972, the first detailed study of the unique behavior of acyclic Z-enediynes upon
thermal activation was described (23). It was realized that a simple enediyne A (Fig. 5),
when heated in solution, gave benzene-related products C, depending on the solvent
used. Bergman (23) recognized the importance of the highly unstable 1,4-didehydro rad-
ical B, responsible for the abstraction of two atoms from the accessible donor (e.g. sol-
vent), leading to the stable benzene structure C (Fig. 5).
Bergman cycloaromatization (23) invoked a great deal of interest among physical
organic and theoretic chemists, but experienced a real revival with the discovery of ene-
diyne anticancer antibiotics. Cycloaromatization of enediyne functionality, the cause of
the DNA cleavage, make enediyne compounds unique in the group of chemotherapeutic
agents. Combined experimental and computational methods were used to determine the
factors that affect reactivity of Z-enediynes in the Bergman reaction and they can be clas-
sified as follows (25):
 cd distance; distance between the two terminal acetylenic carbons (Fig. 5),
 difference in strain energy between the enediyne and the transition state,
 concentration of the trapping agents,
 substituent effects.
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Fig. 5. Bergman cycloaromatization of acyclic enediynes.
Cyclic enediynes generally undergo the Bergman reaction at considerably lower
temperatures than the acyclic ones. It was postulated that, in the absence of other fac-
tors, the interatomic cd distance is the factor that determines the rate of the Bergman re-
action. For example, enediynes with a cd value between 3.20 and 3.30 Å cyclize sponta-
neously at room temperatures, while those with cd > 3.70 Å do not. Thus, shortening the
cd value is a way to overcome the energy gap necessary for the cyclization. It can easily
be achieved by complexation with transition metals allowing smooth control of the cd
value by means of ionic radii (26). Also, it was found that substituents at the terminal
acetylenic carbons have significant influence on the energy of the Bergman cyclization,
while those attached to the vinyl carbons generally have no influence.
Contrary to cyclic enediynes, the main factor determining the rate of the Bergman
cyclization of acyclic endiynes seems to be the difference in the strain energy between
the enediyne and the transition state. Also, the solvent used and the concentration of hy-
drogen donors are to be taken into account when comparing cyclization rates of differ-
ent enediyne compounds.
Designed DNA-cleavers – enediyne anticancer antibiotics modifications
Enediyne anticancer antibiotics are extremely potent DNA cleavers, but highly toxic,
so there is an urgent need for new enediyne-related structures with maximum activity
towards tumor cells and minimum toxicity towards normal cells. Also, structural com-
plexity of natural enediynes calls for synthetically more accessible analogs. There are
two main criteria of efficient artificial DNA cleavers: molecular recognition measured in
selectivity and DNA scission scaled in activity (27).
Having in mind the three main structural and functional domains of enediyne com-
pounds, modifications are directed toward:
 design of new enediyne »warheads« with better control over the cycloaromatiza-
tion mechanism,
 selective recognition and target-directed delivery system,
 triggering device sensitive to chemical or photo-induced activation (28).
Enediyne warheads. – Nicolaou and co-workers (29) synthesized the first generation
of designed enediynes (I in Fig. 6) in order to define the simplest model still capable to
cleave the DNA molecule. It was shown that the derivative with a 10-membered ring (n
= 2) undergoes the Bergman cyclization at room temperature while those with larger
rings (n = 3–8) were stable. Contrary to that, Nicolaou and co-workers were not able to
synthesize a derivative with a 9-membered ring (n = 1). Following these findings, the
water-soluble derivative II (Fig. 6) was prepared and it was found that it undergoes
Bergman cycloaromatization at 37 °C and cleaves double-stranded DNA.
Maier and co-workers (30) have prepared the bicyclic derivative III (Fig. 6), which
is stable at room temperature, but cyclization occurred at elevated temperature. It was
found that metal ions facilitate thermally induced Bergman cyclization of stable ene-
diynes through coordination or complexation. Thus, the molybdenum derivative of ene-
diyne IV (Fig. 6) is far more susceptible to cyclization than the free ligand (31).
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Delivery system. – To ensure delivery of the enediyne model system to the site of ac-
tion, they have been attached to numerous molecules that are known to interact with the
DNA. The hybrid molecule composed of simple cyclic arene enediyne and synthetic a
minor-groove binder structure was found to cleave single-stranded DNA at 40 °C (32).
Also, coupling of simple cyclic enediyne with an analogue of netropsin, minor-groove
DNA binder, gave a hybrid molecule with 2000-fold increased DNA cleaving efficiency
compared to an enediyne alone (33).
Specific elimination of cancer cells by the treatment with chemotherapeutics is usu-
ally hindered by their low selectivity. Recent approaches tend to overcome this draw-
back by using antibody-targeted strategy in cancer therapy. This strategy is based on co-
njugates of cytotoxic agents and antibodies specific for a tumor-associated antigen. Many
experiments have showed increased DNA cleaving activity and cancer cell growth inhi-
bition by such immunoconjugates.
Triggering device. – Bergman cycloaromatization is of great utility if one has control
over it. Thus, extensive work has been done in searching for adequate triggering mecha-
nisms. Simple dynemicin model compound V (Fig. 7) gave a product of Bergman cyc-
lization upon epoxide opening in the presence of an acid catalyst. Dynemicin model VI
(Fig. 7) can be activated photochemically under neutral conditions, while the presence of
a base triggers cycloaromatization of VII (Fig. 7) (25).
In recent years, considerable effort has been invested into understanding the photo-
chemical aspect of Bergman cycloaromatization and thereby into the development of
enediyne compounds equipped with suitable photo-labile groups. Upon irradiation with
visible or UV light without metal ions or reducing agents, these compounds are expect-
ed to form reactive diradicals capable of DNA cleavage.
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Fig. 6. Examples of some designed enediynes.
NATURALLY OCCURING ENEDIYNES
Neocarzinostatin
The natural antibiotic neocarzinostatin (NCS) was first reported in 1965 (34), when it
was isolated from Streptomyces carzinostaticus Var. F-41. It is a complex consisting of a 1:1
non-covalently associated mixture of protein (NCS apoprotein) and a chromoforic (NCS
chromophore) component (Fig. 8). It was soon recognised that chromophoric moiety
yields biological activity and that NCS apoprotein stabilizes and transports the drug (19).
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Fig. 7. Dynemicin model compounds with different triggers.
NCS apoprotein consists of a 113 amino acid polypeptide chain. It binds firmly and
specifically to the chromophore and delivers chromophore to the site of action, the DNA
molecule, by controlled release. It was also reported (35) that NCS apoprotein possesses
cytotoxic activity; it acts upon proteolytic activity.
Potent antitumor and antibacterial activity of NCS is manifested through the DNA
cleavage. NCS chromophore intercalates into the DNA with its naphtoate side chain,
which positions the rest of the molecule within the minor groove. Biologically active free
NCS chromophore moiety cuts single-strands of the DNA, which is followed by an oxy-
gen-dependent reaction. Cleaving properties of the NCS chromophore are greatly en-
hanced by thiols and UV radiation (17).
The mechanism by which the NCS chromophore destroys the DNA (Fig. 9) was first
proposed in 1987 (18). The cascade of reactions that leads to the destruction of the DNA
begins with the stereospecific nucleophilic attack at C(12), e.g., thiols. This triggering
event is followed by the rearrangement of the ring skeleton and epoxide opening; it
leads to the formation of cumulene structure 2. This incurred highly strained and reac-
tive intermediate undergoes instant cycloaromatization and forms the diradical 3. The
diradical thereupon attacks DNA with abstraction of DNA’s two hydrogen atoms, which
results in 4.
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Fig. 9. Triggering pathway for the NCS chromophore.
The role of the NCS apoprotein is clearly seen in information provided by the three-
-dimensional solution structure of intact NCS. The aminomethyl group of the sugar pen-
dant is forced into close proximity of C(12). The reason is a salt bridge with asparagine
33 in a polypeptide chain. Nucleophilic attack may be aided by basic nitrogen of aspa-
ragine and sterical interferences at C(12) of the amino acids serine 98, asparagine 33 and
phenylalanine 52 in a polypeptide chain. This results in positioning the epoxide in a hy-
drophobic pocket away from acid catalysts.
DNA damage induced by the formation of diradical 3 occurs at two abstraction
points in the deoxyribose. The first abstraction point, which causes 80% of DNA cleav-
ages, is C(5’) atom of adenine and thymine residues. Less than 20% of strand breaks re-
sult after the abstraction of hydrogen atom from C(1’) and C(4’). When single-strand
DNA cuts appear, usually the C(5’) hydrogen is abstracted by C(6) in the diradical 3,
whereas double strand DNA lesions involve additional C(1’) or C(4’) abstraction by the
C(2) radical.
Recently, it was observed that thiol independent DNA cleavage is possible. It hap-
pens when a DNA molecule contains regions where double-stranded structures are gener-
ated intramolecularly and, thus, appear as single-strands. If that is the case, DNA would
be a participant in its own destruction (18).
NCS is actually a prodrug that requires sulfhydryl activation for the activity (Fig. 9),
which results in lower selectivity and cytotoxic activity. Initial clinical trials were hin-
dered by anaphylactic responses due to its non-covalently bound protein component. To
prevent this alergic reaction, NCS protein has been rendered immunologically inert by
coupling to a maleic acid-based polymer (SMANCS) and is clinically used primarily in
the treatment of hepatocellular carcinoma (36).
Calicheamicins
The calicheamicins (Fig. 10) are a family of enediyne antibiotics isolated from Micro-
monospora echinospora spp. calichensis. They were identified in 1986 through a research
program that identified microbial fermentation products active in the biochemical in-
duction assay (20).
Calicheamicin g1I is the most distinguished member of this class of compounds.
Calicheamicins with iodine, which are obtained by treating a fermentation broth with
sodium iodide, have shown better yields than the ones containing bromine. The caliche-
amicins are extremely active against Gram-positive bacteria and highly active against
Gram-negative bacteria. Most importantly, they exhibit extraordinary activity against
murine tumors, such as leukemia and solid neoplasms (37). The calicheamicins are pro-
foundly potent sequence specific, double strand DNA-cleaving agents.
The chemical structure of calicheamicin g1I (Fig. 10) can be divided into two distinct
structural regions, containing three essential components. The larger of the two struc-
tural regions consists of an oligosaccharide sugar part (four monosaccharide units) and
one hexasubstituted benzene ring. These two are joined together through a highly un-
usual series of glycosidic, thioester and hydroxylamine linkages. The second structural
region, the aglycon (termed calicheamicinone), contains a highly functionalized bicyclic
core accommodating a strained enediyne unit within a bridging 10-membered ring. It
also contains a trisulfide moiety, which acts as a triggering device.
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The aryltetrasaccharide delivers the drug to its target, binding tightly into the minor
groove of double-helical DNA, displaying high specificity for sequences 5’-TCCT-3’ and
5’-TTTT-3’ through significant hydrophobic interactions (38, 39). This binding is facili-
tated by transformation of the oligosaccharide component into an inflexible, extended
conformation, which provides distinctive torsion angles in the central region of the mole-
cule, necessary to complement the minor groove of the DNA. The DNA appears to dis-
tort itself upon binding, in order to accommodate the drug (induced fit). In addition to
the sequence recognition by an aglycone and aryl oligosaccharide part, large and pola-
rizable iodine in the hexasubstituted benzene ring takes part in the recognition process
as well.
As mentioned above, aglycone is a rigid bicyclic core, a 10-membered ring contain-
ing enediyne moiety awaiting activation to undergo cycloaromatization. It contains an
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Calicheamicin X R1 R2 R3
Calicheamicin b1Br Br Rha Ami CHMe2
Calicheamicin g1Br Br Rha Ami Et
Calicheamicin a1I I H Ami Et
Calicheamicin a3I I Rha H H
Calicheamicin b1I I Rha Ami CHMe2
Calicheamicin g1I I Rha Ami Et
Calicheamicin d1I I Rha Ami Me
Fig. 10. Calicheamicin family.
allylic trisulfide as well, which serves as a trigger. When the drug comes into the vicinity
of the DNA, a nucleophile (e.g., glutathione) attacks the central sulfur atom in the allylic
trisulfide. This leads to the formation of a thiol, which adds intramolecularly to the
neighbouring a,b-unsaturated ketone incorporated within the bicyclic core (Fig. 4). The
change in structural geometry of an aglycone leads to a great deal of strain of the 10-
-membered enediyne ring. At this point, the Bergman cycloaromatization takes place,
forming a highly reactive 1,4-benzenoid diradical. The calicheamicin diradical abstracts
hydrogen atoms from both DNA strands: C(5’) position of the cytidine and C(4’) of the
three base pairs removed on the 3’ side of the complementary strand. Hence, the cleav-
age of both DNA strands occurs.
Natural calicheamicins are a thousand times more potent than conventional cyto-
toxic chemotherapeutics. The calicheamicin g1I has been coupled with antibodies to tu-
mor-specific antigens and has been proposed as a targeted therapy for breast cancer (40).
The first clinically validated cytotoxic immunoconjugate in which a humanized anti-
-CD33 antibody is linked to a calicheamicin derivate is called gentuzumab ozogamicin.
It is indicated for the treatment of elderly patients with relapsed acute myeloid leukae-
mia. A similar conjugate, inotuzumab ozogamicin, is presently in Phase I clinical trials in
patients with non-Hodgkin’s lymphoma. Today, a number of tumor-targeted immuno-
conjugates of calicheamicin are being researched preclinically.
Esperamicins
Esperamicins are a subgroup of naturally occurring enediyne antibiotics. They be-
speak high efficiency as broad-spectrum antibiotics and antitumor agents. Esperamicins
were isolated from the fermentation broth of Actinomadura verrucosospora (21). The name
of this enediyne group was derived from the place where the producing organism was
collected, Pto Esperanza in Argentina.
The molecular structure of the esperamicin family (Fig. 11) was cleared in 1987. The
resemblance of the structure of esperamicins to the structure of calicheamicins is quite
astonishing; they differ from calicheamicins only in an additional hydroxyl group in the
bicyclic core and rather unusual structural motifs in sugar appendages. Other than simi-
larity in structure, they also have similarities in biological activity and mode of action.
Like calicheamicins, esperamicins exert their biological activity by damaging the
DNA. The mechanism of DNA cleavage by esperamicin A1, the most eminent represen-
tative of the esperamicin family, is identical to the DNA cleavage of calicheamicin g1I
(Fig. 4) (41). However, esperamicin A1 exhibits less sequence selectivity than calicheami-
cin g1I. The activity of esperamicin A1 towards DNA is significantly enhanced by thiols,
such as dithiothretiol, and results in single and double strand cuts. The sugar append-
ages assist the drug binding into the minor groove of the DNA, just like in the case of
calichemicin g1I, while pro-radical carbon atoms of the enediyne moiety in the bicyclic
core are positioned towards the C(4’) and C(5’) hydrogen atoms, where abstraction oc-
curs (Fig. 12).
The esperamicins are among the most powerful antitumor agents known. They ex-
hibit a forceful activity against a number of murine tumor models. Despite the number
of side effects, esperamicin A1 has successfully passed Phase I and is now in Phase II
clinical trials.
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Dynemicins
The member of the dynemicin family of enediyne antibiotics that was first discov-
ered is dynemicin A (Fig. 13). This is a violet-colored solid isolated from the fermenta-
tion broth of Micromonospora chersina (22). Its molecular structure was fully determined
in 1989 with the exception of absolute configuration, which was confirmed later on by
total synthesis. Dynemicin A exhibits high efficiency against a variety of cancer cell lines
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Esperamicin n R1 R2 R3
Esperamicin A1 3 H Ar CHMe2
Esperamicin A1b 3 H Ar Et
Esperamicin A1c 3 H Ar Me
Esperamicin P 4 H Ar CHMe2
Esperamicin A2 3 Ar H CHMe2
Esperamicin A2b 3 Ar H Et
Esperamicin A2c 3 Ar H Me
Fig. 11. The esperamicin family.
Fig. 12. Esperamicin A1 bound to the minor groove of the DNA (42).
and prolongs significantly the life span of mice inoculated with leukemia and melanoma
cells (43). Moreover, dynemicin A and its derivates exhibit antibacterial activity in vivo
with low toxicity. Recently, another member of the dynemicin family emerged as a bio-
active compound. Deoxydynemicin A (Fig. 13) was isolated from Micromonospora globosa
and has a similar biological profile as dynemicin A (18).
The molecular structure of dynemicins includes a 10-membered ring with enediyne
moiety embedded within an anthraquinone chromophore, typical of anthracycline anti-
biotics, e.g., doxorubicin. Intercalation of the anthraquinone portion of dynemicin A into
the minor groove of the DNA is the first step in a cascade reaction that leads to DNA
cleavage. This intercalation is associated with local distortion of the DNA in order to ac-
commodate the drug; the dynemicin molecule recognizes conformationally flexible re-
gions of the DNA and acts as a »molecular wedge«. Anthraquinone then undergoes bio-
reduction to give the anthraquinol. The electron-rich anthraquinol is now able to open
the epoxide moiety, which is accompanied with rapid cycloaromatization of the enediy-
ne moiety. 1,4-Benzenoid diradical strips hydrogen atoms from the DNA, resulting in
single and double-helix cleavages (18, 44). The potency of cycloaromatization is enhanc-
ed by thiols and light irradiation and the preferred sites of dynemicin A attacks are 3’
sides of purine bases, such as 5’-AG, 5’-GC, 5’-GT and 5-AT.
Dynemicin A is currently in Phase III clinical trials. Prodrugs of dynemicin A are
much more interesting than dynemicin A alone, because of the possibility to activate
them by aldolase antibody 38C2 specifically inside tumor cells (43).
CONCLUSIONS
Enediyne anticancer antibiotics and their derivatives are considered to be lead can-
didates in combating one of the major diseases today. Calicheamicin seems to be head-
ing most directly to clinical studies, compared to the other enediynes. Efforts to attach
calicheamicin to various drug antibody conjugates that seem suitable for clinical trials
make calicheamicin an enediyne of interest. At the same time, exploring the genomes of
147
M. Gredi~ak and I. Jeri}: Enediyne compounds – new promises in anticancer therapy, Acta Pharm. 57 (2007) 133–150.













two soul microbes, genes that govern the production of enediynes are disclosed. This
finding will, by all means, allow improvement in the production but also in the develop-
ment of new enediyne-related compounds with DNA cleaving ability.
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S A @ E T A K
Endiinski spojevi – novi antitumorski lijekovi
MATIJA GREDI^AK i IVANKA JERI]
Znanstvenici raznih profila dugo su bili intrigirani prirodom, mehanizmom djelo-
vanja i potencijalom prirodnih toksina s izuzetnom antibakterijskom i antitumorskom
aktivno{}u. Ti spojevi, nazvani endiini, danas su me|u najaktivnijim kemoterapeutskim
agensima. ^esto uspore|ivani s inteligentnim oru`jem, zbog jedinstvene strukture i so-
fisticiranog mehanizma kojim uni{tavaju molekulu DNA, endiinski antibiotici danas pred-
stavljaju vode}e spojeve u antitumorskoj terapiji. Predstavnici endiinske skupine spojeva
su u klini~koj primjeni, premda je njihova primjena ograni~ena slo`enom strukturom, {to
ih ~ini zahtjevnim ciljem za sintetske kemi~are. Ovaj rad daje pregled prirodnih endiina, me-
hanizma njihova djelovanja i sintetskih analoga sa sposobno{}u cijepanja molekule DNA.
Klju~ne rije~i: endiini, antitumorsko djelovanje, Bergmanova ciklizacija, cijepanje DNA
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